CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

luspatercept

Last Updated: May 13, 2021
Result type: Reports
Project Number: SR0669-000
Product Line: Reimbursement Review

Generic Name: luspatercept

Brand Name: Reblozyl

Manufacturer: Celgene Inc. / Bristol-Myers Squibb Canada Co.

Therapeutic Area: beta-thalassemia associated anemia

Indications: For the treatment of adult patients with red blood cell (RBC) transfusion-dependent anemia associated with beta(β)-thalassemia

Manufacturer Requested Reimbursement Criteria1: For the treatment of adult patients with -thalassemia associated anemia who require red blood cell (RBC) transfusions.

Submission Type: Initial

NOC Status at Filing: Post NOC

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open October 29, 2020
Call for patient/clinician input closed December 17, 2020
Clarification:

- Patient input submission received from the Thalassemia Foundation of Canada and Canadian Organization for Rare Disorders (CORD)

Submission received November 26, 2020
Submission accepted December 10, 2020
Review initiated December 11, 2020
Clarification:

- Selected for CADTH/INESSS Joint Clinician Engagement

Draft CADTH review report(s) provided to sponsor for comment March 09, 2021
Deadline for sponsors comments March 18, 2021
CADTH responses on draft review report(s) provided to sponsor April 09, 2021
Expert committee meeting (initial) April 21, 2021
Draft recommendation issued to sponsor May 03, 2021
Draft recommendation posted for stakeholder feedback May 13, 2021
End of feedback period May 28, 2021
Final recommendation issued to sponsor and drug plans June 08, 2021
Final recommendation posted June 24, 2021
Deadline for sponsor to submit redaction requests on draft CADTH review report(s) June 22, 2021
CADTH review report(s) posted -